NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike in September. The Dow Jones Industrial Average dropped 0.34 percent to close at 25,733.60, while the S&P 500 Index have declined 0.04 percent to close at 2,861.82. The Nasdaq Composite Index increased 0.38 percent to close at 7,889.10.
"Overall, nothing here to surprise the markets," said Paul Ashworth, chief U.S. economist at Capital Economics. "Attention will now switch to Chair Jerome Powell's Jackson Hole speech this Friday. We expect him to deliver the same message on tightening evident in the minutes. We doubt that President Trump's criticism is going to change anything," referring to President Trump's comments that he is "not thrilled" with the Fed’s movement in raising interest-rate.
RDI Initiates Coverage on:
Conatus Pharmaceuticals Inc.
Sarepta Therapeutics, Inc.
Conatus Pharmaceuticals' stock moved 2.74% higher Wednesday, to close the day at $4.13. The stock recorded a trading volume of 253,695 shares, which was below its three months average volume of 470,481 shares. In the last year, Conatus Pharmaceuticals' shares have traded in a range of 3.22 - 7.95. The share price has gained 28.26% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.22 is below its 200-day moving average of $4.64. Shares of Conatus Pharmaceuticals have fallen roughly 6.35 percent in the past month and are down 10.61 percent year-to-date.
Access RDI's Conatus Pharmaceuticals Inc. Research Report at:
On Wednesday, shares of Sarepta Therapeutics recorded a trading volume of 615,308 shares, which was below the three months average volume of 1,580,296 shares. The stock ended the day 4.1% higher at $134.44. The share price has fallen 23.83% from its 52-week high with a 52-week trading range of 35.52 - 176.50. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $129.63 is above its 200-day moving average of $96.74. Shares of Sarepta Therapeutics have gained roughly 0.85 percent in the past month and are up 141.62 percent year-to-date.
Access RDI's Sarepta Therapeutics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.